oprelvekin

Also known as Neumega, AGIF, IL-11, Adipogenesis inhibitory factor, Interleukin-11 precursor

Oprelvekin is recombinant interleukin eleven (IL-11), a thrombopoietic growth factor that directly stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production. It is marketed under the trade name Neumega.

In the Vinony graph

Vinony's link graph records 204 inbound references to oprelvekin, and connects out to edema, Interleukin 2 and Colony stimulating factor 2.

Vinony files it under Chemicals that do not have a ChemSpider ID assigned, Cytokines and Drugboxes which contain changes to verified fields.

Vinony links it to 9 Wikipedia language editions.

Research

71 papers

Oprelvekin.2012
Oprelvekin. Genetics Institute.Current opinion in investigational drugs (London, England : 2000) · 2001
Oprelvekin-associated bilateral optic disk edema.American journal of ophthalmology · 2005
Oprelvekin (Neumega), first platelet growth factor for thrombocytopenia.Journal of the American Pharmaceutical Association (Washington, D.C. : 1996) · 1999
Oprelvekin: an alternative treatment for thrombocytopenia.Clinical journal of oncology nursing · 1999

via PubMed

Wikidata facts

Show 1 more fact

defined daily dose: 3.5

Sources (3)

via Wikidata · CC0

~10 min read

Encyclopedic overview

11 sections

Contents

Chemical, pharmacological and marketing data
Indications
Contraindications and precautions
Pregnancy
Lactation
Side effects
Interactions
Necessary examinations during treatment
Dosage regimen
Additional information
References

==Chemical, pharmacological and marketing data== IL-11 is a member of a family of human growth factors and is being produced in the bone marrow of healthy adults. Synonyms are: AGIF Adipogenesis inhibitory factor Interleukin-11 precursor.

Excerpted from Wikipedia’s “oprelvekin” article, available under the CC BY-SA 4.0 licence.